跳至主要内容
临床试验/NCT00541333
NCT00541333暂停1 期

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

The New York Eye & Ear Infirmary1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
暂停
入组人数
15
试验地点
1
主要终点
Total drusen area reduction

研究概览

简要总结

The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Dry AMD in one or both eyes
  • Age 50 or above of either gender
  • Signed informed consent.

排除标准

  • Known sensitivity to Mannitol or Copaxone.
  • Skin disease or active infection of skin.
  • Active fever or active treatment for infection.
  • History of other uncontrolled systemic active disease.
  • Premenopausal females not using reliable birth control.
  • Sensitivity to fluorescein or iodine.
  • Inability to comply with study procedures.

研究组 & 干预措施

Copaxone

Active Comparator

干预措施: Copaxone Injection (Drug)

Sham

Sham Comparator

干预措施: Copaxone Injection (Drug)

结局指标

主要结局

Total drusen area reduction

时间窗: 1 year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验